Loading the comparison…
Loading the comparison…
Recovery & Repair
The most-discussed healing peptide, built on a stomach-protein fragment.
Recovery & Repair
A recombinant follistatin analog engineered to bind myostatin and activin.
BPC-157 is not FDA-approved and rated 2/5 for evidence; Flgr-242 is not FDA-approved and rated 1/5. BPC-157 has more human evidence behind it. BPC-157 is banned in sport by WADA; Flgr-242 is not. Both are used for recovery & repair goals.
| Compare | BPC-157 The most-discussed healing peptide, built on a stomach-protein fragment. | Flgr-242 A recombinant follistatin analog engineered to bind myostatin and activin. |
|---|---|---|
| Category | Recovery & Repair | Recovery & Repair |
| Evidence | 2/5Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). | 1/5No published human, animal, or in‑vitro studies specific to FLGR‑242; only background on follistatin biology. |
| FDA status | Not FDA-approved | Not FDA‑approved |
| WADA (sport) | Banned | Not on the Prohibited List |
| Also known as | Body Protection Compound-157, Bepecin, PL 14736 | FLGR242, Follistatin FLGR242 |
| How it works | Appears to up-regulate growth-factor receptors (VEGFR2, growth hormone receptor), promote new blood vessel formation (angiogenesis), and modulate nitric-oxide signaling. Exact human pharmacology is not established. | The peptide binds myostatin and activin, blocking their interaction with activin type‑II receptors and thereby reducing SMAD2/3 signaling that suppresses muscle protein synthesis. |
| Half-life | Short (hours); effects thought to be local + signaling driven | Unknown: no published data (sellers claim about 2–3 weeks) |
| Commonly reported doses |
| |
| Route | Subcutaneous, near injury site | – |
| Good once mixed | ~28 days in the fridge | No published dose yet |
| Top side effects |
| |
| Lowest research-listing price per mg | $2.40 (10 mg vial, 40% off) | – |
| Latest lab purity | 99.61% (lot BP0002) | – |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about BPC-157 and Flgr-242. It answers from these same pages, with links back here.
BPC-157 is not FDA-approved and rated 2/5 for evidence; Flgr-242 is not FDA-approved and rated 1/5. BPC-157 has more human evidence behind it. BPC-157 is banned in sport by WADA; Flgr-242 is not. Both are used for recovery & repair goals.
BPC-157: Not FDA-approved. Flgr-242: Not FDA‑approved. Regulations change, so confirm with the FDA.
BPC-157 is rated 2 out of 5: Dozens of rodent studies; only tiny human pilot data (e.g. knee pain retrospective, IV safety pilot). Flgr-242 is rated 1 out of 5: No published human, animal, or in‑vitro studies specific to FLGR‑242; only background on follistatin biology. The scale is explained on our methodology page.
BPC-157 is banned by WADA, by name or as part of a named class. Flgr-242 is not named on the WADA list, though the general rule on non-approved substances (S0) can still apply.